Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Liver fibrosis affects the targeting properties of drug delivery systems to macrophage subsets in vivo.

Ergen C, Niemietz PM, Heymann F, Baues M, Gremse F, Pola R, van Bloois L, Storm G, Kiessling F, Trautwein C, Luedde T, Lammers T, Tacke F.

Biomaterials. 2019 Jun;206:49-60. doi: 10.1016/j.biomaterials.2019.03.025. Epub 2019 Mar 22.

PMID:
30925288
2.

Liposomal dexamethasone inhibits tumor growth in an advanced human-mouse hybrid model of multiple myeloma.

Deshantri AK, Fens MH, Ruiter RWJ, Metselaar JM, Storm G, van Bloois L, Varela-Moreira A, Mandhane SN, Mutis T, Martens ACM, Groen RWJ, Schiffelers RM.

J Control Release. 2019 Feb 28;296:232-240. doi: 10.1016/j.jconrel.2019.01.028. Epub 2019 Jan 22.

PMID:
30682443
3.

Lipid-mediated Wnt protein stabilization enables serum-free culture of human organ stem cells.

Tüysüz N, van Bloois L, van den Brink S, Begthel H, Verstegen MM, Cruz LJ, Hui L, van der Laan LJ, de Jonge J, Vries R, Braakman E, Mastrobattista E, Cornelissen JJ, Clevers H, Ten Berge D.

Nat Commun. 2017 Mar 6;8:14578. doi: 10.1038/ncomms14578.

4.

Sonoporation enhances liposome accumulation and penetration in tumors with low EPR.

Theek B, Baues M, Ojha T, Möckel D, Veettil SK, Steitz J, van Bloois L, Storm G, Kiessling F, Lammers T.

J Control Release. 2016 Jun 10;231:77-85. doi: 10.1016/j.jconrel.2016.02.021. Epub 2016 Feb 12.

5.

Distribution of technetium-99m PEG-liposomes during oligofructose-induced laminitis development in horses.

Underwood C, Pollitt CC, Metselaar JM, Laverman P, van Bloois L, van den Hoven JM, Storm G, van Eps AW.

Vet J. 2015 Nov;206(2):218-25. doi: 10.1016/j.tvjl.2015.07.013. Epub 2015 Jul 20.

PMID:
26403954
6.

MPLA incorporation into DC-targeting glycoliposomes favours anti-tumour T cell responses.

Boks MA, Ambrosini M, Bruijns SC, Kalay H, van Bloois L, Storm G, Garcia-Vallejo JJ, van Kooyk Y.

J Control Release. 2015 Oct 28;216:37-46. doi: 10.1016/j.jconrel.2015.06.033. Epub 2015 Jul 4.

PMID:
26151293
7.

In situ Delivery of Tumor Antigen- and Adjuvant-Loaded Liposomes Boosts Antigen-Specific T-Cell Responses by Human Dermal Dendritic Cells.

Boks MA, Bruijns SCM, Ambrosini M, Kalay H, van Bloois L, Storm G, Gruijl T, van Kooyk Y.

J Invest Dermatol. 2015 Nov;135(11):2697-2704. doi: 10.1038/jid.2015.226. Epub 2015 Jun 17.

8.

Liposomal delivery of dexamethasone attenuates prostate cancer bone metastatic tumor growth in vivo.

Kroon J, Buijs JT, van der Horst G, Cheung H, van der Mark M, van Bloois L, Rizzo LY, Lammers T, Pelger RC, Storm G, van der Pluijm G, Metselaar JM.

Prostate. 2015 Jun;75(8):815-24. doi: 10.1002/pros.22963. Epub 2015 Feb 8.

9.

Cross-presentation through langerin and DC-SIGN targeting requires different formulations of glycan-modified antigens.

Fehres CM, Kalay H, Bruijns SC, Musaafir SA, Ambrosini M, van Bloois L, van Vliet SJ, Storm G, Garcia-Vallejo JJ, van Kooyk Y.

J Control Release. 2015 Apr 10;203:67-76. doi: 10.1016/j.jconrel.2015.01.040. Epub 2015 Feb 2.

PMID:
25656175
10.

Possibilities and limitations of current technologies for quantification of biological extracellular vesicles and synthetic mimics.

Maas SL, de Vrij J, van der Vlist EJ, Geragousian B, van Bloois L, Mastrobattista E, Schiffelers RM, Wauben MH, Broekman ML, Nolte-'t Hoen EN.

J Control Release. 2015 Feb 28;200:87-96. doi: 10.1016/j.jconrel.2014.12.041. Epub 2014 Dec 30.

11.

Liposomal encapsulation of dexamethasone modulates cytotoxicity, inflammatory cytokine response, and migratory properties of primary human macrophages.

Bartneck M, Peters FM, Warzecha KT, Bienert M, van Bloois L, Trautwein C, Lammers T, Tacke F.

Nanomedicine. 2014 Aug;10(6):1209-20. doi: 10.1016/j.nano.2014.02.011. Epub 2014 Mar 7.

PMID:
24607939
12.

MRI of ICAM-1 upregulation after stroke: the importance of choosing the appropriate target-specific particulate contrast agent.

Deddens LH, van Tilborg GA, van der Toorn A, van der Marel K, Paulis LE, van Bloois L, Storm G, Strijkers GJ, Mulder WJ, de Vries HE, Dijkhuizen RM.

Mol Imaging Biol. 2013 Aug;15(4):411-22. doi: 10.1007/s11307-013-0617-z.

PMID:
23400400
13.

Nanoclusters of iron oxide: effect of core composition on structure, biocompatibility, and cell labeling efficacy.

van Tilborg GA, Cormode DP, Jarzyna PA, van der Toorn A, van der Pol SM, van Bloois L, Fayad ZA, Storm G, Mulder WJ, de Vries HE, Dijkhuizen RM.

Bioconjug Chem. 2012 May 16;23(5):941-50. doi: 10.1021/bc200543k. Epub 2012 May 3.

14.

Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells.

Unger WW, van Beelen AJ, Bruijns SC, Joshi M, Fehres CM, van Bloois L, Verstege MI, Ambrosini M, Kalay H, Nazmi K, Bolscher JG, Hooijberg E, de Gruijl TD, Storm G, van Kooyk Y.

J Control Release. 2012 May 30;160(1):88-95. doi: 10.1016/j.jconrel.2012.02.007. Epub 2012 Feb 15.

PMID:
22366522
15.

Contribution of classic and alternative effector pathways in peanut-induced anaphylactic responses.

Smit JJ, Willemsen K, Hassing I, Fiechter D, Storm G, van Bloois L, Leusen JH, Pennings M, Zaiss D, Pieters RH.

PLoS One. 2011;6(12):e28917. doi: 10.1371/journal.pone.0028917. Epub 2011 Dec 14.

16.

Overcoming cellular multidrug resistance using classical nanomedicine formulations.

Kunjachan S, Błauż A, Möckel D, Theek B, Kiessling F, Etrych T, Ulbrich K, van Bloois L, Storm G, Bartosz G, Rychlik B, Lammers T.

Eur J Pharm Sci. 2012 Mar 12;45(4):421-8. doi: 10.1016/j.ejps.2011.08.028. Epub 2011 Sep 1.

PMID:
21907796
17.

Intravenous technetium-99m labelled PEG-liposomes in horses: a safety and biodistribution study.

Underwood C, van Eps AW, Ross MW, Laverman P, van Bloois L, Storm G, Schaer TP.

Equine Vet J. 2012 Mar;44(2):196-202. doi: 10.1111/j.2042-3306.2011.00403.x. Epub 2011 Jun 23.

PMID:
21696436
18.

DC-SIGN mediated antigen-targeting using glycan-modified liposomes: formulation considerations.

Joshi MD, Unger WW, van Beelen AJ, Bruijns SC, Litjens M, van Bloois L, Kalay H, van Kooyk Y, Storm G.

Int J Pharm. 2011 Sep 20;416(2):426-32. doi: 10.1016/j.ijpharm.2011.02.055. Epub 2011 Mar 1.

PMID:
21371544
19.

Improving solubility and chemical stability of natural compounds for medicinal use by incorporation into liposomes.

Coimbra M, Isacchi B, van Bloois L, Torano JS, Ket A, Wu X, Broere F, Metselaar JM, Rijcken CJ, Storm G, Bilia R, Schiffelers RM.

Int J Pharm. 2011 Sep 20;416(2):433-42. doi: 10.1016/j.ijpharm.2011.01.056. Epub 2011 Feb 1.

PMID:
21291975
20.

Betulinic acid delivered in liposomes reduces growth of human lung and colon cancers in mice without causing systemic toxicity.

Mullauer FB, van Bloois L, Daalhuisen JB, Ten Brink MS, Storm G, Medema JP, Schiffelers RM, Kessler JH.

Anticancer Drugs. 2011 Mar;22(3):223-33. doi: 10.1097/CAD.0b013e3283421035.

PMID:
21263311
21.

A novel approach to identify non-palpable breast lesions combining fluorescent liposomes and magnetic resonance-guided high intensity focused ultrasound-triggered release.

Oerlemans C, Nijsen F, van Amersfoort M, van Bloois L, Heijman E, Luijten P, Mali W, Storm G.

Eur J Pharm Biopharm. 2011 Apr;77(3):458-64. doi: 10.1016/j.ejpb.2010.12.028. Epub 2010 Dec 31.

22.

Multimodal clinical imaging to longitudinally assess a nanomedical anti-inflammatory treatment in experimental atherosclerosis.

Lobatto ME, Fayad ZA, Silvera S, Vucic E, Calcagno C, Mani V, Dickson SD, Nicolay K, Banciu M, Schiffelers RM, Metselaar JM, van Bloois L, Wu HS, Fallon JT, Rudd JH, Fuster V, Fisher EA, Storm G, Mulder WJ.

Mol Pharm. 2010 Dec 6;7(6):2020-9. doi: 10.1021/mp100309y. Epub 2010 Nov 8.

23.

Administration of prednisolone phosphate-liposomes reduces wound contraction in a rat partial-thickness wound model.

Richters CD, Paauw NJ, Mayen I, van Bloois L, Metselaer JM, Storm G, du Pont JS, Hoekstra MJ, Kreis RW, Kamperdijk EW.

Wound Repair Regen. 2006 Sep-Oct;14(5):602-7.

PMID:
17014673
24.

Human regulatory T cells control xenogeneic graft-versus-host disease induced by autologous T cells in RAG2-/-gammac-/- immunodeficient mice.

Mutis T, van Rijn RS, Simonetti ER, Aarts-Riemens T, Emmelot ME, van Bloois L, Martens A, Verdonck LF, Ebeling SB.

Clin Cancer Res. 2006 Sep 15;12(18):5520-5.

25.

Targeting liposomes with protein drugs to the blood-brain barrier in vitro.

Visser CC, Stevanović S, Voorwinden LH, van Bloois L, Gaillard PJ, Danhof M, Crommelin DJ, de Boer AG.

Eur J Pharm Sci. 2005 Jun;25(2-3):299-305. Epub 2005 Apr 18.

PMID:
15911226
26.

Coupling of metal containing homing devices to liposomes via a maleimide linker: use of TCEP to stabilize thiol-groups without scavenging metals.

Visser CC, Voorwinden LH, Harders LR, Eloualid M, van Bloois L, Crommelin DJ, Danhof M, de Boer AG.

J Drug Target. 2004;12(9-10):569-73.

PMID:
15621682
27.

Enhanced engraftment of human cells in RAG2/gammac double-knockout mice after treatment with CL2MDP liposomes.

Rozemuller H, Knaän-Shanzer S, Hagenbeek A, van Bloois L, Storm G, Martens AC.

Exp Hematol. 2004 Nov;32(11):1118-25.

PMID:
15539091
28.

A liposomal system for contrast-enhanced magnetic resonance imaging of molecular targets.

Mulder WJ, Strijkers GJ, Griffioen AW, van Bloois L, Molema G, Storm G, Koning GA, Nicolay K.

Bioconjug Chem. 2004 Jul-Aug;15(4):799-806.

PMID:
15264867
29.

A new xenograft model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2-/- gammac-/- double-mutant mice.

van Rijn RS, Simonetti ER, Hagenbeek A, Hogenes MC, de Weger RA, Canninga-van Dijk MR, Weijer K, Spits H, Storm G, van Bloois L, Rijkers G, Martens AC, Ebeling SB.

Blood. 2003 Oct 1;102(7):2522-31. Epub 2003 Jun 5.

PMID:
12791667
30.

Functional characterization of an endosome-disruptive peptide and its application in cytosolic delivery of immunoliposome-entrapped proteins.

Mastrobattista E, Koning GA, van Bloois L, Filipe AC, Jiskoot W, Storm G.

J Biol Chem. 2002 Jul 26;277(30):27135-43. Epub 2002 May 20.

31.

Synovial macrophage depletion with clodronate-containing liposomes in rheumatoid arthritis.

Barrera P, Blom A, van Lent PL, van Bloois L, Beijnen JH, van Rooijen N, de Waal Malefijt MC, van de Putte LB, Storm G, van den Berg WB.

Arthritis Rheum. 2000 Sep;43(9):1951-9.

32.

Cellular uptake of liposomes targeted to intercellular adhesion molecule-1 (ICAM-1) on bronchial epithelial cells.

Mastrobattista E, Storm G, van Bloois L, Reszka R, Bloemen PG, Crommelin DJ, Henricks PA.

Biochim Biophys Acta. 1999 Jul 15;1419(2):353-63.

33.

Intravenous administration of superoxide dismutase entrapped in long circulating liposomes. II. In vivo fate in a rat model of adjuvant arthritis.

Corvo ML, Boerman OC, Oyen WJ, Van Bloois L, Cruz ME, Crommelin DJ, Storm G.

Biochim Biophys Acta. 1999 Jul 15;1419(2):325-34.

34.

Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells.

Toes RE, van der Voort EI, Schoenberger SP, Drijfhout JW, van Bloois L, Storm G, Kast WM, Offringa R, Melief CJ.

J Immunol. 1998 May 1;160(9):4449-56.

35.

Thermodynamic analysis of the interaction between a bactericidal antibody and a PorA epitope of Neisseria meningitidis.

van den Elsen JM, van Unen LM, van Bloois L, Busquets MA, Jiskoot W, Hoogerhout P, Wilting J, Herron JN, Crommelin DJ.

Biochemistry. 1997 Oct 14;36(41):12583-91.

PMID:
9376364
36.

Scintigraphic evaluation of experimental colitis in rabbits.

Oyen WJ, Boerman OC, Dams ET, Storm G, van Bloois L, Koenders EB, van Haelst UJ, van der Meer JW, Corstens FH.

J Nucl Med. 1997 Oct;38(10):1596-600.

37.

Technetium-99m labelled liposomes to image experimental arthritis.

Boerman OC, Oyen WJ, Storm G, Corvo ML, van Bloois L, van der Meer JW, Corstens FH.

Ann Rheum Dis. 1997 Jun;56(6):369-73.

38.

Optimization of technetium-99m-labeled PEG liposomes to image focal infection: effects of particle size and circulation time.

Boerman OC, Oyen WJ, van Bloois L, Koenders EB, van der Meer JW, Corstens FH, Storm G.

J Nucl Med. 1997 Mar;38(3):489-93.

39.
40.

Labelled Stealth liposomes in experimental infection: an alternative to leukocyte scintigraphy?

Oyen WJ, Boerman OC, Storm G, van Bloois L, Koenders EB, Crommelin DJ, van der Meer JW, Corstens FH.

Nucl Med Commun. 1996 Sep;17(9):742-8.

PMID:
8895901
41.

Detecting infection and inflammation with technetium-99m-labeled Stealth liposomes.

Oyen WJ, Boerman OC, Storm G, van Bloois L, Koenders EB, Claessens RA, Perenboom RM, Crommelin DJ, van der Meer JW, Corstens FH.

J Nucl Med. 1996 Aug;37(8):1392-7.

42.

Sterically stabilized liposomes labeled with indium-111 to image focal infection.

Boerman OC, Storm G, Oyen WJ, van Bloois L, van der Meer JW, Claessens RA, Crommelin DJ, Corstens FH.

J Nucl Med. 1995 Sep;36(9):1639-44.

43.

Adhesion molecules: a new target for immunoliposome-mediated drug delivery.

Bloemen PG, Henricks PA, van Bloois L, van den Tweel MC, Bloem AC, Nijkamp FP, Crommelin DJ, Storm G.

FEBS Lett. 1995 Jan 3;357(2):140-4.

44.
45.

The role of protein charge in protein-lipid interactions. pH-dependent changes of the electrophoretic mobility of liposomes through adsorption of water-soluble, globular proteins.

Bergers JJ, Vingerhoeds MH, van Bloois L, Herron JN, Janssen LH, Fischer MJ, Crommelin DJ.

Biochemistry. 1993 May 4;32(17):4641-9.

PMID:
8485142
46.

Subcutaneous administration of HMG-CoA reductase inhibitors in hyperlipidaemic and normal rats.

Joles J, Willekes-Koolschijn N, Koomans H, Van Tol A, Geelhoed-Mieras T, Crommelin D, Van Bloois L, Krajnc-Franken M, Cohen L, Griffioen M, et al.

Lab Anim. 1992 Oct;26(4):269-80.

PMID:
1447905
47.

The interaction of cytostatic drugs with adsorbents in aqueous media. The potential implications for liposome preparation.

Storm G, van Bloois L, Brouwer M, Crommelin DJ.

Biochim Biophys Acta. 1985 Sep 10;818(3):343-51.

PMID:
2412582

Supplemental Content

Loading ...
Support Center